Objective: Alterations to the N-glycans in glycoproteins have been suggested to play important roles in the proliferation, differentiation, invasion and metastasis of hepatocellular carcinoma (HCC). This study aims to evaluate the potential prognostic value of β1,6-N-acetylglucosaminyltransferase V (Mgat5) in hepatocellular carcinoma patients after surgical resection. Methods: We retrospectively enrolled 300 patients (156 in the training cohort and 144 in the validation cohort) with hepatocellular carcinoma undergoing hepatectomy at a single institution. Mgat5 intensities were assessed by immunohistochemistry in the specimens of patients. The Kaplan-Meier method was applied to compare survival curves. Cox regression models were used to analyze the impact of prognostic factors on overall survival and recurrence-free survival. The concordance index was calculated to assess predictive accuracy. Results: Intratumoral Mgat5 expression was significantly higher than non-tumoral tissues (P < 0.001). In both cohorts, elevated Mgat5 expression in tumor tissues positively correlated with vascular invasion and advanced tumor-node-metastasis stage. High Mgat5 expression indicated poor survival (P < 0.001 in the training cohort and P < 0.001 in the validation cohort) and recurrence (P < 0.001 in both cohorts, respectively) in patients with hepatocellular carcinoma, particularly with early-stage disease. Mgat5 expression was identified as an independent adverse prognostic factor for survival and recurrence. The predictive accuracy of tumor-node-metastasis and Barcelona Clinic Liver Cancer prognostic models was improved when Mgat5 expression was added. Conclusion: Mgat5 expression is a potential independent adverse prognostic biomarker for recurrence and survival of patients with hepatocellular carcinoma after hepatectomy.
Introduction
Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide and among the leading causes of cancer-related death, especially in China (1) . Although surgical therapy offers the main treatment for prolonging patient survival, a high postoperative recurrence rate is a major problem (2) . It will be beneficial if we could predict each patient's malignant potential and prognosis from the surgical specimen obtained in the initial surgery. Because of a noted heterogeneity among patients within the same HCC stage, conventional tumor-node-metastasis (TNM) staging system is insufficient to predict HCC recurrence (3) . Therefore, molecular approaches to stratifying patients with HCC, through integration of biomarkers into staging system parameters, are expected to better predict patient survival and refine their prognostic stratification (4) .
Glycosylation is a common post-translational modification of proteins, and variation in oligosaccharide structures is associated with malignant transformation and tumor progression (5) . N-glycans are widely distributed on cell surfaces and secreted glycoproteins, where structural change is observed in development, carcinogenesis and malignant transformation (6) . Modifications of N-glycans in cancer cells are associated with cell adhesion, invasion and metastasis (7) . Of note, increased levels of tetra-antennary glycan were observed in liver tumor tissue compared with adjacent or non-diseased tissue (8) . The branching is catalyzed by the medial Golgi β1,6-N-acetylglucosaminyltransferase V (Mgat5), initiating the fourth branch in a sequential pathway to tetraantennary N-glycans (9) .
Mgat5 products are preferentially recognized by the plant lectin L-phytohemagglutinin (L-PHA) from Phaseolus vulgaris (10) . Mgat5 expression in carcinoma was rate limiting for cytokine signaling and consequently for epithelial-mesenchymal transition (EMT), cell motility and tumor metastasis (11) . Furthermore, Mgat5 glycan products stimulated membrane ruffling and phosphatidylinositol 3 kinase-protein kinase B activation, fueling a positive feedback loop that amplified oncogene signaling and tumor growth (12) . Mgat5 deficiency inhibited the polyomavirus middle T antigen (PyMT)-induced tumor metastasis (13) . On the other hand, it has been shown that the forced expression of Mgat5 in epithelial cells results in a loss of contact inhibition, increased cell motility and morphological transformation in culture (7) .
Mgat5 overexpression promotes tumorigenesis (14, 15) , while an Mgat5-deficient suppresses mammary tumor growth and metastasis in polyoma middle T transgenic mice (11, 12) . Mgat5 mRNA levels are increased in the liver of a rodent model of hepatocarcinogenesis as well as in a regenerative liver (16) . Increased activity of Mgat5 in human hepatocellular carcinoma tissues also was reported, and positive correlation to TNM classification of HCC was observed (17) . These findings were contradicted by the study of Ito et al. which showed a reversed expression level in early and advanced HCC (18) . However, protein expression and localization of Mgat5 in human tumor and peritumoral HCC tissues have not yet been well documented.
In this study, we assessed the expression of Mgat5 in surgical specimens and their predictive values for recurrence in HCC patients after curative resection, as an attempt to determine whether they are involved in the progression of HCC and thus be useful as molecular prognostic markers and therapeutic targets for HCC.
Materials and methods

Patients
A total of 300 patients who underwent curative hepatectomy for HCC at Huashan Hospital, Fudan University (Shanghai, China) were enrolled in the study. Specimens of the training cohort (n = 156) were obtained from April 2003 through May 2004, and specimens of the validation cohort (n = 144) were obtained from June 2004 through July 2005. The study was approved by the research medical ethics committee of Fudan University and informed consent was provided by each patient. All cases conformed with the following criteria: diagnosed by postoperative histopathology; complete follow-up data available; no extrahepatic metastasis; no other malignant diseases; no preoperative anticancer therapy. Curative resection was defined as complete resection of all tumor nodules and the cut surface being free of cancer by histologic examination, having no cancerous thrombus in the portal vein (main trunk or two major branches), hepatic veins or bile duct; and having no extrahepatic metastasis (19) . Patients were reassigned according to the 7th edition of tumor, node, metastasis (TNM) classification system of the American Joint Committee on Cancer/International Union Against Cancer. Tumor differentiation was assessed according to the Edmonson and Steiner grading system. Data were censored at the last follow-up for patients without recurrence or death. Overall survival (OS) was calculated from the date of surgery to the date of death or the last follow-up. Recurrences were defined as the emergence of one or several liver-enhancing foci on computed tomography or magnetic resonance imaging (20) . None of these patients died from operative complications or from other factors. The last follow-up was in August 2010, with a median follow-up of 45.5 months (range, 1.0-77.0 months) in the training cohort, and 44.0 months (range, 2.0-64.0 months) in the validation cohort.
Tissue microarray and immunohistochemistry
Tissue microarrays (TMAs) were constructed as previously described (21) . Briefly, representative areas free from necrotic and hemorrhagic materials were premarked in the paraffin blocks. Two core biopsies of 1 mm in diameter were taken from the donor blocks and transferred to the recipient paraffin block at defined array positions. Primary anti-Mgat5 antibody (1:100; Sigma-Aldrich, St Louis, MO, USA) was used for immunohistochemistry staining. Before immunohistochemistry staining, the specificity of antibody was confirmed by immunohistochemistry with peptide competition. A certified pathologist (Z.H.) who was blinded to the clinical data assessed Mgat5 immunostaining. The ARIOL imaging system (Leica Microsystems, Wetzlar Germany) was used to quantify Mgat5 staining of the TMAs. The specimens were scanned at a low resolution (×1.25) and high resolution (×20) using a Leica DM5000B microscope with an automated platform. A cytoplasmic high-resolution classifier was created and trained for the Mgat5 staining. The classifier consisted of color class definition for positive, negative and background, and a shape class definition for the HCC cells. The color class was defined by the hue, saturation and intensity parameters, whereas the shape class was defined by the spot width, width, compactness and axis ratio parameters. The Mgat5 high-resolution classifier was trained in several areas within a tissue sample in order to avoid miscalculation due to differences in staining and cell composition. Among tissue samples, the classifier was always trained and recalibrated under the visual supervision of the pathologist (Z.H.). The number of cells stained was calculated and represented as a percentage of total cells/nuclei stained positively. By measuring both immunostaining intensity and percentage, data obtained are reproducible, objective measurements of immunoreactivity. A semi-quantitative H-score for each sample was calculated multiplying the staining intensities (0: negative, 1: weak staining, 2: moderate staining, 3: strong staining) by the distributions (0-100%), and ranged from 0 to 300 (22) . The median value of the H-score was chosen as the cutoff criterion in the training cohort. In the validation cohort, we dichotomized Mgat5 expression using the same cut point as for the training cohort.
Construction of the nomogram
In the training cohort, variables that achieved significance at P < 0.05 were entered into the multivariable analyses via the Cox regression model. Statistical analyses to identify independent prognostic factors were conducted in SPSS 17.0 for Windows (SPSS, Chicago, IL, 
Validation and calibration of the nomogram
The nomogram was subjected to internal validation of the primary training cohort and external validation with the validation cohort. The model performance for predicting outcome was evaluated by calculating the concordance index (c-index). The value of the c-index ranges from 0.5 to 1.0, with 0.5 indicating a random chance and 1.0 indicating a perfect ability to correctly discriminate the outcome with the model.
Statistical analysis
Statistical analysis was performed using MedCalc software (version 12.7.0.0; MedCalc, Mariakerke, Belgium). Numerical data were analyzed using Student's t-test, and categorical data were studied using Fisher's exact or a χ 2 test. Cumulative survival time was calculated by the Kaplan-Meier method and analyzed by a log-rank test. Numbers at risk were calculated for the beginning of each time period. Possible factors associated with each end point were first identified by a screening process by univariate analysis. For each end point, variables with a P value <0.05 in the univariate analysis were entered into stepwise Cox regression multivariate models. The predictive accuracy of the models was measured by the Harrell's c-index. The Akaike information criterion (24) value was applied to measure the discriminatory ability of each prognostic model (25) . All tests were two-sided and used a significance level of P values of <0.05.
Results
Immunohistochemical findings
To ascertain whether Mgat5 was differentially expressed in HCC tissues, we searched and analyzed the expression level of Mgat5 in HCC using the Oncomine Cancer Microarray database (http://www. oncomine.org) (26) . In the dataset of Mas et al. (27) , Mgat5 mRNA expression is upregulated in HCC (Supplementary data, Fig. S1 ). Mgat5 expression was detected by immunohistochemical staining analysis in 300 patients with HCC in the training and the validation cohort. Specific expression of cytoplasmic Mgat5 was observed in both non-tumor and tumor tissues, and the staining intensity was variable (Fig. 1A ) . Compared with the non-tumoral Mgat5 density in hepatocytes, tumoral Mgat5 density was higher (P < 0.001, Fig. 1B) . Furthermore, the intensity of tumoral Mgat5 expression increased as disease progression increased from TNM stage I-III (Fig. 1C) . Collectively, these observations suggest that Mgat5 expression in tumor tissues might be connected with clinical progression of HCC.
Association of Mgat5 expression with clinicopathologic variables in HCC patients
As presented in Table 1 , Mgat5 expression was associated with more vascular invasion (P = 0.037 in the training cohort, and P < 0.001 in the validation cohort, respectively), higher tumor classification (P < 0.001 in both cohorts) and higher TNM stage (P = 0.002 in the training cohort, and P < 0.001 in the validation cohort, respectively) and had no significant relationship with any other clinicopathological characteristics. Consistently, Mgat5 expression was associated with vascular invasion, higher tumor classification and higher TNM stage in the all cohort. However, non-tumoral Mgat5 expression did not correlate with any other clinicopathological features (Supplementary data, Table S1 ).
Prognostic value of Mgat5 intensity for clinical outcome of HCC patients
To further investigate the prognostic value of Mgat5 expression in HCC patients, we applied Kaplan-Meier survival analysis and a logrank test to compare OS and recurrence-free survival (RFS) between
Mgat5 high-and low-expression subgroups in the two cohorts. High expression level of Mgat5 was significantly associated with worse survival (P < 0.001 in the training cohort and P < 0.001 in the validation cohort; Fig. 2A and B) and recurrence (P < 0.001 in the training cohort and P = 0.003 in the validation cohort; Fig. 3A and B) . We further investigated whether Mgat5 expression could stratify patients with different TNM stage in an overall cohort of 300 patients. The dichotomized Mgat5 level was found to show strong prognostic relevance for TNM stage I patients, both for OS (P < 0.001, Fig. 2C ) and RFS (P < 0.001, Fig. 3C ). However, it failed to predict OS and RFS of TNM stage II-III patients (P = 0.222 and P = 0.072, respectively; Figs 2D and 3D) . In contrast to tumoral Mgat5 expression, nontumoral Mgat5 expression did not correlate with OS and RFS in the two cohorts (Supplementary data, Fig. S2 )
Mgat5 expression is an independent prognostic factor in HCC patients
To determine the prognostic significance of clinicopathological variables for OS and RFS, we performed univariate Cox analysis. As presented in Supplementary data, Table S2 , Mgat5 expression was identified as a risk factor that might affect OS (hazard ratio (HR) 2.69, P < 0.001 in the training cohort; HR 2.722, P < 0.001 in the validation cohort) and RFS (HR 2.174, P < 0.001 in the training cohort; HR 2.474, P < 0.001 in the validation cohort) of HCC patients. In addition, alpha-fetoprotein (AFP), tumor size, vascular invasion, T classification, TNM stage and Barcelona Clinic Liver Cancer (BCLC) were identified as unfavorable factors for OS in the training and the validation cohort. Furthermore, tumor size, vascular invasion, T classification, TNM stage and BCLC were identified as unfavorable factors for RFS in both cohorts. Because BCLC stage was associated with the three clinical categories of tumor characteristics, liver function and performance status, it was not included in multiple analyses to avoid potential bias. To further estimate the robust prognostic value of Mgat5 expression, multivariate Cox regression analysis including clinicopathological variables showing significance in univariate analysis was conducted. As shown in Table 2 , Mgat5 expression was identified as an independent prognostic factor for OS (HR 1.749, P = 0.039 in the training cohort, and HR 2.556, P = 0.002 in the validation cohort) and RFS (HR 1.653, P = 0.039 in the training cohort, and HR 2.724, P < 0.001 in the validation cohort). In conclusion, Mgat5 expression could be an independent prognostic factor for HCC patients.
Association between Mgat5 expression and clinical outcome in TNM stage I patients
To evaluate the clinical usefulness of Mgat5 expression in early-stage HCC, we performed subgroup analysis upon TNM stage I patients. By univariate analysis, AFP (P = 0.006), tumor size (P < 0.001), advanced BCLC stage (P < 0.001) and high Mgat5 expression (P < 0.001) were significantly associated with worse OS (Table 3 ). In addition, tumor size (P < 0.001), advanced BCLC stage (P < 0.001) and higher Mgat5 expression (P < 0.001) were significantly associated with short RFS (Table 3 ). Multivariate analysis showed that higher AFP (HR 3.048, P = 0.008), advanced BCLC stage (HR 2.529, P = 0.019) and Mgat5 expression (HR 5.114, P < 0.001) were significantly associated with worse OS (Table 3) . Advanced BCLC stage (HR 2.352, P = 0.026) and higher Mgat5 expression (HR 2.941, P < 0.001) were significantly associated with short RFS (Table 3) .
Prognostic nomogram for OS
A nomogram that incorporated the significant prognostic factors was established (Table 4 and Supplementary data, Fig S3) . The nomogram illustrated T category and tumor size as sharing the largest contribution to prognosis, followed by differentiation and Mgat5. Each subtype within these variables was assigned a score on the point scale.
In the training cohort, the Harrell's c-index for the established nomogram including Mgat5 to predict OS (0.77) was higher than that of the nomogram without Mgat5 (0.749). In the validation cohort, the c-index was also greater for the nomogram including Mgat5 (0.731) than for the nomogram without Mgat5 (0.708).
Extension of prognostic models with Mgat5 expression for HCC patients
To further assess the predictive power of Mgat5 expression, we constructed prognostic models combining Mgat5 expression with TNM stage and BCLC stage, respectively, and compared the predictive accuracy of these models by c-index and Akaike information criteria (AIC) analysis. As presented in Table 5 Bold values indicate P < 0.05. AFP, alpha-fetoprotein; OS, overall survival; RFS, recurrence-free survival; HR, hazard ratio; CI, confidence interval.
Discussion
In the present study, we detected the expression of Mgat5 in HCC using 300 surgical specimens of two cohorts, and found that high Mgat5 expression was positively associated with TNM stage and impaired clinical outcome. Moreover, Mgat5 expression was identified as a potential independent poor prognostic factor for OS and RFS of HCC patients. In addition, subgroup analysis showed that Mgat5 overexpression is more closely related to worse clinical outcome in early-stage patients compared with all study subjects. Therefore, Mgat5 expression could serve as a potential stratification factor for screening out high-risk patients who need more intensive follow-up and aggressive therapies. Although the mechanism by which Mgat5 is associated with poor survival in HCC patients cannot be fully explained, increased tumor invasiveness by Mgat5 offers a possible explanation. EMT and glycan of cell surface glycoproteins play pivotal roles in tumor metastasis (28) . β1,6-GalNAc branching and tetra-antennary complex oligosaccharide structures play a central role in EMT, and thus Mgat5 could facilitate the malignant behavior and aggressiveness of tumor cells (29) . Mgat5 overexpression is related to an early tumorigenesis of HCC (18) . Similarly, our data showed that the presence of vascular invasion tended to be associated with increased Mgat5 expression. These observations pose the question, which molecular mechanisms relevant for tumor progression are affected by elevated Mgat5 products.
Partridge et al. reported that Mgat5-modified N-glycans containing poly-N-acetyllactosamine, the preferred ligand for galectin-3, on surface receptors avoid their constitutive endocytosis, resulting in promotion of intracellular signaling and consequently cell migration and tumor metastasis (11) . For instance, galectin-3 cross-links Mgat5-modified N-glycans on epidermal growth factor (EGFR) and transforming growth factor-β receptors and by this delays their removal from the cell membrane by constitutive endocytosis (30) . Our previous study revealed that surface levels of EGFR family members are commonly increased in HCC, and correlate with increased Mgat5 expression (31) . Another important pathway involves the modulation of homotypic cell-cell adhesion by affecting the β1,6 branched N-glycans in α5β1-integrins, causing these cells to be less adhesive on fibronectin, but more motile and invasive through matrigel (32) .
Mgat5 expression is upregulated in early stages of almost all cancers (33) as its transcription is stimulated by several oncogenes such as src (34) , her-2/neu (35), H-ras and V-sis (36) . Oncogenic transformation increases gene expression of Mgat5, which appears to reduce the requirement for hexosamine supplementary by supporting higher levels of tri-and tetra-antennary N-glycan biosynthesis in Mgat5 overexpression tumor cells (37) . This overexpression is regulated by the ras-raf-ets, protein kinase c and phosphatidylinositol 3-kinase-protein kinase B pathways (30, 38) . The role of ras-raf-ets pathway in the upregulation of Mgat5 in the development of HCC remains further study. Bold values indicate P < 0.05. HBsAg, hepatitis B surface antigen; ALT, alanine aminotransferase; AFP, alpha-fetoprotein; TNM, tumor node, metastasis classification system; BCLC, the Barcelona Clinic Liver Cancer staging; HR, hazard ratio; CI, confidence interval.
Changes in the expression of glycosytransferases, such as Mgat5, result in altered glycan assembly, which occurs in the endoplasmic reticulum and Golgi. The saccharide structures, such as higher ordered branching of N-linked glycans, are added to normal cellular proteins, resulting in neoglycoforms that can be released through conventional secretory pathways or proteolytic cleavage. It is possible that a portion of these alternatively glycosylated molecules reach the bloodstream. As such, they could serve as early sentinels that enable cancer detection (39) . The appearance of N-and O-linked glycosylation on many glycoproteins presented in the circulation correlates with HCC (40) . N-lined glycosylation of glycoprotein GP73 is a potential biomarker for early detection of HCC (41) . A set of three identified N-glycans is sufficient for the detection of HCC with 90% prediction accuracy in a population with high rates of hepatitis C viral infection using glycomic analysis (42) . Ultimately, the choice and timing of any future glycan-based therapy against cancer should be guided by both serological assays for glycan markers and novel biopsy information. However, the study has its own limitations with its retrospective nature, small and monocentric cohorts, and few patients with metastatic disease. Therefore, our results need to be validated in large, prospective and external datasets.
Supplementary data
Supplementary data are available at http://www.jjco.oxfordjournals. org. The concordance index (c-index) for the training and validation datasets are given for the derived nomograms as a performance measure.
pT, pathologic tumor stage. 
